Payment overview · 2025
General Payments
$235.77
11 reported records · 8 companies
Healthcare provider profile · identity verified
Bradley T Moore, DO
Allopathic & Osteopathic Physicians|Family Medicine · WAYLAND, KY · NPI 1629062807
Verified facts
What the public records show
CMS Open Payments records show Bradley T Moore, DO received $235.77 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Movantik, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
Valinor Pharma, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOVANTIK as an associated drug or biological on 4139 records involving 1847 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Movantik by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.55 | 25.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 19.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $40.52 | 17.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.41 | 8.7% | 1 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $20.37 | 8.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.84 | 8.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.66 | 7.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.42 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $190.77 | 10 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $40.52 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.99 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOVANTIK movantik |
2025 | Movantik | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
94 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 13 |
| Valinor Pharma, LLC Exact reporting entity; no affiliate inference |
2025 | MOVANTIK open payments reported associated product |
CMS Open Payments — General Payments 4139 supporting records · 1847 recipient NPIs · example record 1248445875 |
Movantik · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 617 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 605 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 55 |
| Lisinopril | Lisinopril | 370 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 353 | 49 |
| Losartan Potassium | Losartan Potassium | 329 | 52 |
| Omeprazole | Omeprazole | 274 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 45 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 245 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 234 | 35 |
| Metformin Hcl | Metformin Hcl | 218 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 216 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 209 | 23 |
| Montelukast Sodium | Montelukast Sodium | 208 | 33 |
| Furosemide | Furosemide | 187 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 183 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 176 | 28 |
| Pregabalin | Pregabalin | 175 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 29 |
| Famotidine | Famotidine | 157 | 25 |
| Clonazepam | Clonazepam | 153 | 15 |
| Potassium Chloride | Potassium Chloride | 139 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 107 | 11 |
| Diazepam | Diazepam | 105 | 14 |
| Simvastatin | Simvastatin | 103 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 19 |
| Trazodone Hcl | Trazodone Hcl | 99 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 18 |
| Mounjaro | Tirzepatide | 94 | 19 |
| Meloxicam | Meloxicam | 93 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 11 |
| Allopurinol | Allopurinol | 90 | 16 |
| Ibuprofen | Ibuprofen | 86 | 16 |
| Alprazolam | Alprazolam | 84 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 11 |
| Carvedilol | Carvedilol | 79 | 14 |
| Eliquis | Apixaban | 78 | 13 |
| Buspirone Hcl | Buspirone Hcl | 70 | 12 |
| Movantik | Naloxegol Oxalate | 66 | suppressed |
| Ozempic | Semaglutide | 65 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 61 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 61 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 58 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 11 |
| Tramadol Hcl | Tramadol Hcl | 56 | 14 |
| Donepezil Hcl | Donepezil Hcl | 55 | suppressed |
| Linzess | Linaclotide | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 42 |
| Jardiance | Empagliflozin | 51 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | suppressed |
| Finasteride | Finasteride | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 49 | suppressed |
| Dutasteride | Dutasteride | 45 | suppressed |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Cephalexin | Cephalexin | 43 | 32 |
| Atenolol | Atenolol | 42 | suppressed |
| Celecoxib | Celecoxib | 42 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Sucralfate | Sucralfate | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Prednisone | Prednisone | 37 | 28 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Desloratadine | Desloratadine | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 17 |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Roflumilast | Roflumilast | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Constulose | Lactulose | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $235.77 · 11 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, JARDIANCE, JOURNAVX, MOVANTIK, Ozempic, Rybelsus, VYNDAMAX, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error